Enhabit to Report Q4 and FY 2025 Results on March 4, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy EHAB?
Source: Newsfilter
- Earnings Report Schedule: Enhabit, Inc. will announce its financial results for the fourth quarter and fiscal year 2025 on March 4, 2026, reflecting its ongoing growth and market performance in the home health and hospice sector.
- Conference Call Details: The company will host a webcast and conference call on March 5, 2026, with participants encouraged to join 15 minutes early to ensure timely access to the latest financial information and management insights.
- National Coverage Capability: Enhabit operates 247 home health and 115 hospice locations across 34 states, demonstrating its service capacity and market penetration, which further solidifies its leadership position in the industry.
- Integration of Technology and Care: Enhabit leverages advanced technology and compassionate teams to deliver exceptional patient care, highlighting its strategic importance in enhancing the quality of home healthcare.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EHAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EHAB
Wall Street analysts forecast EHAB stock price to fall
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.600
Low
10.50
Averages
12.20
High
14.00
Current: 13.600
Low
10.50
Averages
12.20
High
14.00
About EHAB
Enhabit, Inc. is a provider of home health and hospice services in the United States. Its segments include Home Health and Hospice. The Home Health segment provides a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. It works closely with patients, families, caregivers, and physicians to deliver data-driven, evidence-based care plans focused on patient needs and goals. Its home health services are provided by nurses, physical, occupational and speech therapists, medical social workers, and home health aides. The Hospice segment provides hospice services to terminally ill patients and their families. Hospice care focuses on the quality of life for patients experiencing an advanced, life- limiting illness by treating the symptoms of the disease, rather than the disease itself. It operates about 115 hospice agencies and 255 home health agencies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Investigation Background: Halper Sadeh LLC is investigating companies such as Arcellx, Inc., Veris Residential, Inc., and Enhabit, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Arcellx Transaction: Arcellx, Inc. is being sold to Gilead Sciences, Inc. for $115.00 per share in cash plus a contingent value right of $5.00 per share, which may limit superior competing offers and affect potential shareholder returns.
- Veris Transaction: Veris Residential, Inc. is being sold for $19.00 per share to an investor consortium led by Affinius Capital and Vista Hill Partners, and Halper Sadeh LLC may seek to increase the consideration to protect shareholder interests.
- Enhabit Transaction: Enhabit, Inc. is being sold to Kinderhook Industries, LLC for $13.80 per share in cash, and Halper Sadeh LLC encourages shareholders to reach out to understand their rights and options to ensure their legal interests are protected.
See More
- Investigation Focus: Halper Sadeh LLC is investigating Enhabit, Inc. (NYSE:EHAB) for its sale to Kinderhook Industries, LLC at $13.80 per share, potentially infringing on shareholder rights, prompting investors to consider their options.
- Merger Impact: Devon Energy Corporation (NYSE:DVN) is merging with Coterra Energy Inc., resulting in Devon shareholders owning approximately 54% of the combined entity, necessitating awareness of the merger's implications on their investments.
- Equity Transaction: LINKBANCORP, Inc. (NASDAQ:LNKB) is selling at a rate of 0.1350 shares of Burke & Herbert common stock for each LINKBANCORP share, with shareholders needing to be aware of how the terms may limit their rights.
- Merger Expectations: CECO Environmental Corp. (NASDAQ:CECO) is merging with Thermon Group Holdings, Inc., with CECO shareholders expected to own about 62.5% of the combined company, urging shareholders to understand the post-merger equity distribution.
See More
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the transaction between Enhabit Inc. and Kinderhook Industries, where Enhabit shareholders are expected to receive $13.80 per share in cash, potentially enhancing shareholder returns significantly.
- Merger Equity Distribution: The merger between CECO Environmental Corp. and Thermon Group Holdings is expected to grant CECO shareholders approximately 62.5% ownership in the combined entity, which could strengthen CECO's competitive position in the market.
- Fair Transaction Assessment: The merger of Laird Superfoods with Navitas LLC is deemed fair to Laird shareholders, indicating that the transaction has been reasonably considered in terms of shareholder interests, which may boost shareholder confidence.
- Cash Acquisition Terms: The deal between SunOpta Inc. and Pegasus BidCo B.V. is expected to provide SunOpta shareholders with $6.50 per share in cash, offering direct financial returns to shareholders and enhancing market recognition of the transaction.
See More
- New Investment Position: AREX Capital Management disclosed in a February 17, 2026 SEC filing that it established a new position in Callaway Golf Company by acquiring 453,000 shares, valued at an estimated $5.29 million, indicating confidence in the company's prospects.
- Significant Holding Proportion: This acquisition positions Callaway to account for 15.03% of AREX's reportable 13F assets, marking its importance within the fund's top five holdings, which may influence future investment strategies.
- Strong Stock Performance: As of February 28, 2026, Callaway shares were priced at $14.06, reflecting a 115.3% increase over the past year, significantly outperforming the S&P 500 by 99.78 percentage points, suggesting optimistic market sentiment regarding its recovery.
- Strategic Restructuring Signal: Following the merger with Topgolf, Leonard Green & Partners acquired a 60% stake in Topgolf in early 2026, and this spinoff aims to help Callaway sharpen its strategic focus, indicating potential for future growth despite inherent risks.
See More
- New Investment Position: On February 17, 2026, AREX Capital Management established a new position in Callaway Golf Company by acquiring 453,000 shares valued at $5.29 million, representing 15.03% of its reportable 13F assets.
- Portfolio Structure Shift: This acquisition positions Callaway as the second-largest holding for AREX, following EHAB, which is valued at $22.99 million and constitutes 65.36% of its AUM, reflecting AREX's confidence in the golf sector.
- Stock Price Recovery: As of February 28, 2026, Callaway's stock price reached $14.06, marking a 115.3% increase over the past year and outperforming the S&P 500 by 99.78 percentage points, indicating optimistic market expectations for future growth.
- Strategic Restructuring Signal: Following its merger with Topgolf in 2021, the acquisition of a 60% stake in Topgolf by Leonard Green & Partners in early 2026 suggests that Callaway is focusing on core operations, potentially enhancing growth prospects, although structural changes may lead to increased volatility.
See More
- UBS Raises Target Price: UBS has increased its target price for a specific asset from $12 to $13.8.
- Market Implications: This adjustment reflects UBS's confidence in the asset's performance and potential growth in the market.
See More






